XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

<p>Abstract</p> <p>Background</p> <p>The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer.</p> <p>Methods</p> <p>Patients previously untreated fo...

Full description

Bibliographic Details
Main Authors: Pectasides Dimitrios, Papaxoinis George, Kalogeras Konstantine T, Eleftheraki Anastasia G, Xanthakis Ioannis, Makatsoris Thomas, Samantas Epaminondas, Varthalitis Ioannis, Papakostas Pavlos, Nikitas Nikitas, Papandreou Christos N, Pentheroudakis George, Timotheadou Eleni, Koutras Angelos, Sgouros Joseph, Bafaloukos Dimitrios, Klouvas George, Economopoulos Theofanis, Syrigos Konstantinos N, Fountzilas George
Format: Article
Language:English
Published: BMC 2012-06-01
Series:BMC Cancer
Subjects:
Angiogenic markers
Bevacizumab
Capecitabine
Chemotherapy
Colorectal cancer
Irinotecan
Online Access:http://www.biomedcentral.com/1471-2407/12/271

Internet

http://www.biomedcentral.com/1471-2407/12/271

Similar Items